CME/CE Activities
Are you in need of CME/CE credit or are you simply looking to advance your education? Browse our list of current CME/CE offerings. All activities are provided FREE OF CHARGE to participants.
Renal Cell Carcinoma
CME Web-Based Virtual Rounds
Earn up to 2.25 AMA PRA Category 1 Credit(s)TM by participating in three 30-minute virtual rounds. Listen to faculty experts Robert J. Motzer, MD, and Robert A. Figlin, MD, while following along with the slides. Learn about first-line treatments, managing disease progression, and evaluating the appropriateness of ongoing clinical trials for your patients.
Click here to learn more...
The Breast Cancer Initiative
Addressing Chemotherapy Resistance
A CME/CE Web-Based Activity
The Breast Cancer Initiative consists of 3 On-Demand, case-based CME/CE workshops that address the lack of standard of care for patients with metastatic disease resistant to anthracyclines and taxanes. Mechanisms of resistance are discussed as a basis for understanding how emerging agents can overcome this resistance. Participants will explore recent data on new treatment options, including the epothilones, a new microtubule-targeting class of agents, and specifically ixebepilone, which was recently the first in this class of agents to gain FDA approval. The safety profiles of these new agents and salvage combination regimens are reviewed, as is the management of associated adverse events. The Breast Cancer Initiative consists of 3 On-Demand, case-based CME/CE workshops that address the lack of standard of care for patients with metastatic disease resistant to anthracyclines and taxanes. Mechanisms of resistance are discussed as a basis for understanding how emerging agents can overcome this resistance. Participants will explore recent data on new treatment options, including the epothilones, a new microtubule-targeting class of agents, and specifically ixebepilone, which was recently the first in this class of agents to gain FDA approval. The safety profiles of these new agents and salvage combination regimens are reviewed, as is the management of associated adverse events.
Click here to learn more.
Renal Cell Carcinoma
A CME-Certified Activity
Earn up to 0.5 AMA PRA Category 1 Credit(s)TM by listening to this prerecorded queston and answer session with Robert J. Motzer, MD, and Robert A. Figlin, MD.
Click here to participate now!
Combination Therapy with mTOR Inhibitors:
Future Directions and Strategic Therapeutic Approaches
Earn up to 1.0 AMA PRA Category 1 CreditTMor 1 Contact Hour of nursing credit for participating in this interactive Internet CME/CE newsletter series. This 2-part series will update oncologists and oncology nurses about the role of mTOR inhibition in current cancer treatment and future combinations of mTOR inhibitors with cytotoxic, endocrine, and targeted therapies. In Issue 1, Dr Motzer reviews the signaling pathways involved, examines the efficacy of mTOR inhibition as monotherapy in renal cell carcinoma, and explores clinical data regarding monotherapy and combination regimens involving mTOR inhibitors in glioma, and in lung and breast cancers.
Click here for Newsletter 1.
Click here for Newsletter 2.
Chronic Myelogenous Leukemia Beyond Imatinib
Overcoming Drug Resistance and Optimizing Therapy in CML
This interactive platform contains web based newsletters and workshops.